IMP321 Phase I Study in Metastatic Breast Carcinoma Patients Receiving First-line Paclitaxel.

Trial Profile

IMP321 Phase I Study in Metastatic Breast Carcinoma Patients Receiving First-line Paclitaxel.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 24 Nov 2015

At a glance

  • Drugs Eftilagimod alpha (Primary) ; Paclitaxel
  • Indications Advanced breast cancer
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors Immutep
  • Most Recent Events

    • 07 Sep 2010 Final results have been published in the Journal of Translational Medicine [8:71, 2010] according to an Immutep media release.
    • 18 Jun 2010 Results have been presented at the 46th Annual Meeting of ASCO, according to an Immutep media release.
    • 12 Jan 2010 Actual end date (Jan 2010) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top